ACTU
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Actuate reported promising preclinical data showing synergistic activity of elraglusib with the RAS inhibitors zoldonrasib and daraxonrasibSep 9, 2026
- Actuate Therapeutics receives FDA IND clearance for oral elraglusib and advances development strategyMay 11, 2026
- Actuate reported Nature Medicine data showing elraglusib plus chemotherapy doubled survival in untreated metastatic pancreatic cancerApr 14, 2026
- Actuate Therapeutics planned expansion of clinical pipeline with elraglusib Phase 1/2 programJan 21, 2026
- Actuate Therapeutics reports positive patient outcomes from Phase 1 trial in hard-to-treat refractory pediatric cancersJan 6, 2026